Post-marketing pharmacovigilance methods: Spontaneous reports and scientifi c literature monitoring (review)
Open Access
- 6 July 2026
- journal article
- Published by SCEEMP in Safety and Risk of Pharmacotherapy
- Vol. 14 (2) , 184-194
Abstract
INTRODUCTION. Many aspects of the drug safety profile, including rare and delayed adverse drug reactions (ADRs), are identified only in the post-marketing period when the drug is used in real-world clinical practice. However, the drawbacks inherent in spontaneous reporting and scientific literature monitoring (the main methods of post-marketing pharmacovigilance), such as incompleteness, fragmentation, variability in data quality, and the lack of standardized approaches to their analysis necessitate the systematization of information and the unification of approaches to data processing. AIM. To systematize information on the spontaneous reporting method and scientific literature monitoring, as well as on data processing approaches in post-marketing pharmacovigilance for risk management and ensuring drug safety. DISCUSSION . Spontaneous reporting is the basic passive method for post-marketing drug safety monitoring, with advantages including broad population coverage and the ability to detect a wide range of ADRs, including rare, delayed, and previously unknown ones. The effectiveness of the spontaneous reporting method can be enhanced through the development of educational programs for healthcare professionals and patients, the implementation of natural language processing (NLP) technologies to automate the extraction of structured information about ADRs from unstructured text sources, and integration with real-world data (RWD) to confirm signals and quantify risks. Scientific literature monitoring serves as a bridge between the passive collection of real-world data and evidence-based findings from controlled studies. An analysis of the EAEU Good Pharmacovigilance Practice Guidelines shows that when searching for information in the scientific literature, special aspects of the drug safety profile must be taken into account: effects on pregnancy outcomes, use in pediatrics, lack of efficacy, overdose, off-label use, and preclinical data. To standardize statistical methods for signal detection and the correct interpretation of signals (disproportionality analysis in spontaneous reporting databases), the READUS-PV guideline (2024) is recommended. CONCLUSIONS. The modern methodology of post-marketing pharmacovigilance is a dynamically evolving system. The presented systematization of approaches to spontaneous reporting and scientific literature monitoring, as well as the list of mandatory drug safety aspects, can serve as a practical tool for specialists in planning and conducting drug safety assessments.Keywords
This publication has 78 references indexed in Scilit:
- Completeness of spontaneously reported adverse drug reactions in 4 databasesBritish Journal of Clinical Pharmacology, 2025
- FDA Adverse Event Reporting System (FAERS) Essentials: A Guide to Understanding, Applying, and Interpreting Adverse Event Data Reported to FAERSClinical Pharmacology & Therapeutics, 2025
- An innovative method to strengthen evidence for potential drug safety signals using Electronic Health RecordsJournal of Medical Systems, 2024
- The Reporting of a Disproportionality Analysis for Drug Safety Signal Detection Using Individual Case Safety Reports in PharmacoVigilance (READUS-PV): Development and StatementDrug Safety, 2024
- The REporting of A Disproportionality Analysis for DrUg Safety Signal Detection Using Individual Case Safety Reports in PharmacoVigilance (READUS-PV): Explanation and ElaborationDrug Safety, 2024
- Adverse drug reaction signal detection methods in spontaneous reporting system: A systematic reviewPharmacoepidemiology and Drug Safety, 2024
- Prevalence, contributing factors, and interventions to reduce medication errors in outpatient and ambulatory settings: a systematic reviewInternational Journal of Clinical Pharmacy, 2023
- Signals of Adverse Drug Reactions Communicated by Pharmacovigilance Stakeholders: A Scoping Review of the Global LiteratureDrug Safety, 2022
- A New Era in Pharmacovigilance: Toward Real‐World Data and Digital MonitoringClinical Pharmacology & Therapeutics, 2021
- EudraVigilance Medicines Safety Database: Publicly Accessible Data for Research and Public Health ProtectionDrug Safety, 2018